CD8A and neoplasm: Under these circumstances, the clinical efficacy of immune modulation via checkpoint inhibitors is essentially influenced by the baseline immune response and by triggering pre-existing immunity, leading to the concept of “hot” and “cold” tumors on the basis of level and spatial distribution of CD3+ and CD8+ T cell infiltration into the tumor [58,59].